论文部分内容阅读
目的:探讨BCL-2和Bax基因表达在宫颈癌新动脉化疗评价中的作用。方法:随机选择60例宫颈癌患者进行研究(动脉化疗组32例,静脉化疗组28例)。采用免疫组化法检测化疗前和化疗后15天宫颈癌组织的凋亡相关基因BCL-2和Bax,并根据病理损伤程度进行疗效评价。结果:动脉化疗组的病理缓解率为81%,与静脉化疗组的53%比较,差异有显著性;通过对动脉化疗前、后肿瘤细胞凋亡相关基因BCL-2、Bax的检测,发现Bax高表达者其病理缓解疗效明显优于Bax低表达者,且动脉化疗后Bax基因表达增加,而静脉化疗前后凋亡相关基因表达的比较却无差异。结论:动脉化疗的疗效优于静脉化疗,Bax基因表达的检测可作为预测患者动脉化疗敏感性的指标之一。
Objective: To investigate the role of BCL-2 and Bax gene expression in the evaluation of neoarterial chemotherapy for cervical cancer. METHODS: Sixty patients with cervical cancer were randomly selected for study (32 in the arterial chemotherapy group and 28 in the intravenous chemotherapy group). The apoptosis-related genes BCL-2 and Bax in cervical cancer tissues before and 15 days after chemotherapy were detected by immunohistochemistry. The curative effect was evaluated according to the degree of pathological injury. Results: The pathological remission rate was 81% in arterial chemotherapy group, which was significantly different from that of 53% in intravenous chemotherapy group. The detection of BCL-2 and Bax in tumor cells before and after arterial chemotherapy showed that Bax The high expression of its pathological response was significantly better than those with low expression of Bax and arterial chemotherapy Bax gene expression increased, while before and after intravenous chemotherapy, apoptosis-related gene expression was no difference. Conclusion: Arterial chemotherapy is better than intravenous chemotherapy. The detection of Bax gene expression can be used as an index to predict the chemosensitivity of patients with arterial chemotherapy.